Altamira Therapeutics

Altamira Therapeutics has news to share! altamiratx.com/news

Altamira Therapeutics has news to share! Altamira Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis

Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China linkedin.com/posts/altamira…

Altamira Therapeutics Announces Collaboration on Circular RNA Delivery globenewswire.com/NewsRoom/Relea…

Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results globenewswire.com/NewsRoom/Relea…

Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025 globenewswire.com/NewsRoom/Relea…

Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent Great news - first patent granted! One step closer to bringing Bentrio to US allergy sufferers. globenewswire.com/NewsRoom/Relea…

Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies globenewswire.com/NewsRoom/Relea…

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA globenewswire.com/NewsRoom/Relea…

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark. lnkd.in/eKtC-AWB

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances.

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models bit.ly/46Jej2Y

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles bit.ly/46e2Hoc

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management bit.ly/3VRbBV6

Altamira Therapeutics Provides Business Update bit.ly/3R7zbdB

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal bit.ly/3wUFdav

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation bit.ly/3UhblwO

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal bit.ly/3QjjAHv

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results bit.ly/3vOklkS